Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COSTEM 2019 | Can CAR-T cells replace ASCT in DLBCL?

Stephen Schuster • 25 Oct 2019
COSTEM 2019
Diffuse Large B-Cell Lymphoma Lymphoma Antibodies CAR-T Rituximab

Stephen Schuster, MD, University of Pennsylvania, Philadelphia, PA, discusses his views on whether CAR-T cells can replace autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Stephen Schuster

CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products
Catherine Bollard et al. • 10 Oct 2024
Where are we going with CARs? 0:50
Where are we going with CARs?
Stephen Schuster • 7 Dec 2019
Mosunetuzumab in B-NHL R/R to CAR-T 1:45
Mosunetuzumab in B-NHL R/R to CAR-T
Stephen Schuster • 7 Dec 2019
Out of specification anti-CD19 CAR T-cell products in aggressive B-cell lymphomas 1:39
Out of specification anti-CD19 CAR T-cell products in aggressive B-cell lymphomas
Stephen Schuster • 7 Dec 2019

Related Videos

Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL 2:11
Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL
Reid Merryman • 8 Dec 2025
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals